EuroIntervention

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions

Thomas Cuisset^{1*}, MD; Harald Mudra², MD; Oliver Muller³, MD PhD; Pierre Vogt³, MD; Anne Angelillo-Scherrer⁴, MD; Kurt Huber⁵, MD

 Department of Cardiology, University Hospital La Timone, Marseille, France; 2. Department of Cardiology, Pulmonology and Internal Intensive Care Medicine, Städtisches Klinikum München GmbH, Klinikum Neuperlach, Munich, Germany;
 Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; 4. Service d'Hématologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 5. Department of Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria

The authors have no conflict of interest to declare.

Introduction

Recent European Society of Cardiology (ESC) Guidelines have extensively investigated antithrombotic therapy during percutaneous coronary interventions (PCI)¹⁻³. However, based on their complexity and partial difference from existing ACC/AHA guidelines, it is sometimes difficult to follow them in individual decisions. Moreover, most of the recommendations are based on prospective randomised trials, which only partially reflect the "real world" situation. Meta-analyses and guideline-based registries might help to guide daily practice. With respect to cardiovascular interventions the combination of both anticoagulant and antiplatelet therapies is mandatory to prevent thrombosis, because activation of both platelets and the coagulation system contribute to thrombus formation. The choice, initiation and duration of antithrombotic strategies is based on the clinical setting (elective, acute or urgent intervention). To optimise efficacy of therapy and reduce the potential bleeding hazard both, ischaemic and bleeding risks, have to be evaluated on an individual basis. The present report aims to give practical solutions to handle antithrombotic therapy for patients undergoing PCI in various clinical conditions.

* Corresponding author: Department of Cardiology, University Hospital La Timone, Boulevard Jean Moulin, Marseille, France E-mail: thomascuisset@voila.fr

© Europa Edition 2008. All rights reserved.



Elective percutaneous coronary intervention

a) Antiplatelet therapy	Aspirin 250 mg bolus i.v. followed by 75 to 100 mg p.o. daily for all patients 1	
	Clopidogrel 300 [600] mg loading dose followed by 75 mg daily for all patients ¹	 A 600 mg clopidogrel loading dose should be used according to its benefit in term of platelet inhibition over the 300 mg standard dose, even if this is given >6h before PCI⁴. Some have suggested the use of a higher maintenance dose (150 mg)⁵ in patients with high thrombotic risk (e.g. in diabetics, patients after recurrent infarction, after early and late stent thrombosis or with complex lesions). However, this approach has not been yet validated in prospective randomized trial, which are currently ongoing.
	GP IIb/IIIa-Inhibitors: Only in "bail-out"- situations (thrombus, no reflow, vessel closure, very complex lesions) ¹ .	Recent trials could not demonstrate any additional benefit of GP IIb/IIIa-inhibitors after a clopidogrel loading dose of 600 mg ^{6,7} .
b) Anticoagulation	UFH is currently the gold standard antithrombotic medication: 70-100 IU/kg i.v. bolus without GP IIb/IIIa-inhibitors, only 50- 70 IU/kg with GP IIb/IIIa-inhibitors ¹ .	The recent STEEPLE trial has suggested a benefit of enoxaparin (0.75 mg/kg i.v. bolus) over UFH with regard to a reduced bleeding hazard ⁸ .

Non ST elevation acute coronary syndrome (NSTE-ACS)

See also: Algorithm of NSTE ACS management (Figure 1) To find the optimal strategy the risk of ischaemic events and the bleeding risk of an individual patient have to be weighed against each other. Thereby, easy to use variables or scores should be preferred.

ASSESSMENT OF PATIENT RISK:

- Higher ischaemic risk:

 $\label{eq:stress} \begin{array}{l} \text{ST-segment changes, elevated troponin, diabetes, GRACE score} \\ > 108^9 \end{array}$

- Higher bleeding risk:

Female, >75 years, bleeding history, GFR<30ml/min, femoral access




Figure 1. NSTE Acute Coronary Syndrome.

PCRONLINE.com

a) Antiplatelet therapy ²	Aspirin 250 mg i.v. bolus followed by 75 to 100 mg daily.	
	 Clopidogrel 600 mg loading dose followed by 75 mg daily. 	A higher clopidogrel maintenance dose has been discussed also in this setting but definitive proof is still missing (see above).
	GP IIb/IIIa-inhibitors should be used in patients with high ischemic risk undergoing PCI.	Although the use of GP IIb/IIIa-inhibitors in this setting is a IA recommendation, "upstream administration" has been mainly investigated in studies without ADP antagonist use ² . The usefulness of upstream therapy, when clopidogrel is on board is not known and currently investigated in the EARLY- ACS trial. GPIIb/IIIa inhibitors have been beneficial only in high-risk NSTE-ACS patients undergoing PCl ² . However, "upstream use" also includes patients, which in the end are not undergoing PCl, might have less or no benefit from this strategy but an increased bleeding risk ¹⁰ . The selective "downstream administration" of abciximab in combination with a 600 mg clopidogrel loading dose has been shown to be effective for troponin-positive (high-risk) NSTE-ACS patients ¹¹ and might therefore be the better choice.
b) Anticoagulation ²	Golden Rules Cross-over between different antithrombins should be avoided ² – Stop antithrombins immediately after PCI except in specific individual situations (e.g. thrombotic complication)	

Pre-cath management

1. In very high risk patients

(e.g. Persistent Angina, Haemodynamic Instability, Refractory Arrhythmias)

Patients are immediately referred to the cathlab:

UFH 60 IU/kg i.v. bolus, then infusion until PCI with GP IIb/IIIa inhibitors (abciximab)

In patients with high bleeding risk: monotherapy with bivalirudin, 0.1 mg/kg i.v. bolus followed by an infusion of 0.25 mg/kg/hr

2. In medium-to-high risk patients (e.g. troponin-positive, recurrent angina, dynamic ST changes)

Primarily invasive strategy is planned <72h:

In patients <75 years

UFH 60 IU/kg i.v. bolus, then infusion (aPTT-controlled) until PCI or enoxaparin 1 mg/kg s.c. twice daily until PCI or fondaparinux 2.5 mg daily s.c. until PCI

In patients > 75 years

UFH 60 IU/kg i.v. bolus, then infusion (aPTT-controlled) until PCI Fondaparinux 2.5 mg daily s.c. In case of renal failure (GFR<30 ml/min) UFH 60 IU/kg i.v. bolus, then infusion (aPTT-controlled) until PCI

3. In low-risk patients

Primarily conservative strategy is planned:

Fondaparinux 2.5 mg s.c. daily or enoxaparin 1 mg/kg s.c. twice daily or UFH 60 IU/kg i.v. bolus, then infusion (aPTT-controlled) until PCI

Management in the cathlab

Golden Rule:

Continue the initial therapy! (Don't switch except after fondaparinux)

If under UFH: Continue perfusion, ACT measurement might be useful Target range: - 200-250 sec with GP IIb/IIIa-inhibitors

- 250-350 sec without GP IIb/IIIa-inhibitors

If under enoxaparin:

< 8h of last s.c. application: no additional bolus within 8-12h of last s.c. application: add 0.30 mg/kg i.v. bolus >12h of last s.c. application: 0.75 mg/kg i.v. bolus

If under bivalirudin: An additional i.v. bolus of 0.5 mg/kg and an increase of the infusion to 1.75 mg/kg/hour before PCI is performed

If under fondaparinux: UFH 50-100 IU/kg when angiography and PCI is performed

PCRONLINE.com

ST elevation myocardial infarction (STEMI)

a) Antiplatelet therapy ³	Aspirin 250 mg bolus i.v. followed by 75 to 100 mg daily	
	Clopidogrel 600 mg loading dose followed by 75 mg daily	Although no study data is available (the CIPAMI trial answering this question is still ongoing), clopidogrel should be started as early as possible – A possibly higher clopidogrel maintenance dose has been discussed (see above)
	GP IIb/IIIa-inhibitors: The best data exist for abciximab (0.25 mg/kg i.v. bolus followed by infusion of 0.125 μ g/kg/min up to a maximum of 10 μ g/min for 12 h)	<i>Clinical data are heterogeneous about the efficiency of facilitation (early administration) with GP IIb/IIIa-inhibitors before cathlab. While the only published randomised trial¹² showed no benefit, we have positive results from registries and metanalyses¹³⁻¹⁵.</i>
b) Anticoagulation ³	UFH 60 IU/kg i.v. bolus with GP IIb/IIIa-inhibitor	
	UFH 100 IU/kg i.v. bolus without GP IIb/IIIa-inhibitor	
	ACT might be useful (target ranges see above)	
	Stop perfusion of antithrombin after PCI, except if specific indication force to continue (left ventricular aneurysm and/or thrombus, atrial fibrillation, prolonged bed rest, deferred sheath removal)	A recent study suggested bivalirudin as alternative to UFH+IIb/IIIa antagonists ¹⁶ . Bivalirudin might be preferred, especially in patients with high bleeding risk.

Specific points of interest

Prevention of bleeding

- Assessment of bleeding risk
- No crossover of antithrombotic therapy
- No overdosing of antithrombotic therapy
- Radial access should be the preferred option in high bleeding risk
- Stop anticoagulation after PCI unless a specific indication exists

– Selective downstream use of GP IIb/IIIa-inhibitors in NSTE ACS might be better than unselective upstream use

- A consensual bleeding risk score is highly warranted

Duration of dual antiplatelet therapy

- After bare metal stent (BMS) implantation in stable angina: one month
- After drug eluting stent (DES) implantation (all patients): one year
- After ACS (all patients independent of therapeutic strategy): one year

Golden rules to avoid premature discontinuation of antiplatelet therapy

- Avoid DES in patients not expected to comply with therapy
- Avoid DES if surgery is planned within 12 months

– Detailed information and education of the patient might prevent premature cessation of antiplatelet therapy

– Most surgical procedures can be performed under dual antiplatelet therapy with acceptable rate of bleeding: a multidisciplinary approach is required (cardiologist, anaesthesiologist, surgeon).

In surgical procedures with high bleeding risk:

– Stop clopidogrel five days before surgery and stay on ASA, unless high bleeding risk surgery

– The substitution of combined antiplatelet therapy with LMWH is ineffective and useless

- Restart clopidogrel as soon as possible with loading dose
 - In very high risk patients (e.g. multivessel DES<1 years, left main

stenting...), in whom cessation of antiplatelet therapy before surgery seems to be dangerous, it has been suggested to switch from clopidogrel five days before surgery to a short half-life antiplatelet agent, e.g. the GP IIb/IIIa-inhibitors tirofiban or eptifibatide and stop infusion of these agents four hours before surgery.

Patient under chronic anticoagulation

To avoid long-term triple antithrombotic therapy, BMS implantation or the use of pure balloon dilatation is preferred over the use of DES.

Antiplatelet therapy monitoring

- No consensual test system available
- No consensual definition of "non"- or "low" response

- No large clinical evidence that tailored antiplatelet therapy improves clinical outcomes

– Monitoring of antiplatelet response by platelet function assays is used at present only in clinical research. Data are not strong enough to support the common use of the available assay systems in daily clinical practice.

Patients with aspirin hypersensitivity

If aspirin is highly required a "rapid desensitisation procedure" should be ${\rm performed}^{17}$

Heparin induced thrombocytopenia (HIT)

In patient with a history of HIT, neither UFH nor LMWH should not be used (cross reactivity). Bivalirudin is the best option in this case for elective PCI and ACS. Others options are argatroban, lepirudin and danaparoid.

References

1. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W;



Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. *Eur Heart J.* 2005;26(8):804-47.

2. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W.Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J.* 2007;28(13):1598-660.

3. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W, Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J.* 2003;24(1):28-66.

4. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. *J Am Coll Cardiol.* 2006;48(5):931-8.

5. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. *Circulation.* 2007;115(6):708-16.

6. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. *N Engl J Med.* 2004;350(3):232-8.

7. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. *Circulation*. 2004;110(24):3627-35.

8. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355(10):1006-17.

9. de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk s.c.ores: sustained prognostic value and interaction with revas.c.ularization in NSTE-ACS. *Eur Heart J* 2005;26: 865-872.

10. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leis.c.h F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD; ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. *JAMA*. 2007;297(6):591-602.

11. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. *JAMA*. 2006;295(13):1531-8.

12. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. *N Engl J Med.* 2008;358(21):2205-17

13. Rakowski T, Dziewierz A, Siudak A, Mielecki W, Legutko J, Janzon M, Birkemeyer R, Depukat R, Dudek D. Early Abciximab Administration Before Primary Percutaneous Coronary Interventions Reduces Mortality but Not in Low-Risk Patients: Results From EUROTRANSFER Registry on ST-Elevation Myocardial Infarction Patients. *J Am Coll Cardiol*, March 11, 2008.

14. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. *JAMA*. 2004;292(3):362-6.

15. De Luca G, Gibson M, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel M, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, Van't Hof A. Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty (EGYPT) cooperation. An individual patients' data meta-analysis. *Heart* 2008, Jun 5. [Epub ahead of print].

16. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong S.C., Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med.* 2008;358(21):2218-30.

17. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. *Am J Cardiol.* 2005;95(4):509-10.

